# A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

> **NCT06662383** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 800 (estimated)

## Conditions studied

- Obesity

## Interventions

- **DRUG:** Retatrutide
- **DRUG:** Tirzepatide

## Key facts

- **NCT ID:** NCT06662383
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2026-04-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06662383

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06662383, "A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06662383. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*